Atrial Fibrillation Pipeline Review, H2 2015 - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Atrial Fibrillation Pipeline Review, H2 2015

Description:

This report provides comprehensive information on the therapeutic development for Atrial Fibrillation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atrial Fibrillation and special features on late-stage and discontinued projects. Enquiry @ – PowerPoint PPT presentation

Number of Views:37

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Atrial Fibrillation Pipeline Review, H2 2015


1
Atrial Fibrillation Pipeline Review, H2 2015
Published on October - 2015
2
.
Report Overview
About Atrial Fibrillation Pipeline Review, H2
2015 Research Beam added report on Atrial
Fibrillation Pipeline Review, H2 2015. Atrial
Fibrillation Pipeline Review, H2 2015
Summary Global Markets Directs, Atrial
Fibrillation Pipeline Review, H2 2015, provides
an overview of the Atrial Fibrillations
therapeutic pipeline. This report provides
comprehensive information on the therapeutic
development for Atrial Fibrillation, complete
with comparative analysis at various stages,
therapeutics assessment by drug target, mechanism
of action (MoA), route of administration (RoA)
and molecule type, along with latest updates, and
featured news and press releases. It also reviews
key players involved in the therapeutic
development for Atrial Fibrillation and special
features on late-stage and discontinued
projects. Get Full Details On
http//www.researchbeam.com/atrial-fibrillation-pi
peline-review-h2-2015-market
3
.
Report Overview
Global Markets Directs report features
investigational drugs from across globe covering
over 20 therapy areas and nearly 3,000
indications. The report is built using data and
information sourced from Global Markets Directs
proprietary databases, Company/University
websites, SEC filings, investor presentations and
featured press releases from company/university
sites and industry-specific third party sources,
put together by Global Markets Directs team. Drug
profiles/records featured in the report undergoes
periodic updation following a stringent set of
processes that ensures that all the profiles are
updated with the latest set of information.
Additionally, processes including live news
deals tracking, browser based alert-box and
clinical trials registries tracking ensure that
the most recent developments are captured on a
real time basis. The report enhances decision
making capabilities and help to create effective
counter strategies to gain competitive advantage.
It strengthens RD pipelines by identifying new
targets and MOAs to produce first-in-class and
best-in-class products. Note Certain sections
in the report may be removed or altered based on
the availability and relevance of data for the
indicated disease.  
4
.
Report Overview
Scope The report provides a snapshot of the
global therapeutic landscape of Atrial
Fibrillation The report reviews key pipeline
products under drug profile section which
includes, product description, MoA and RD brief,
licensing and collaboration details other
developmental activities The report reviews key
players involved in the therapeutics development
for Atrial Fibrillation and enlists all their
major and minor projects The report summarizes
all the dormant and discontinued pipeline
projects A review of the Atrial Fibrillation
products under development by companies and
universities/research institutes based on
information derived from company and
industry-specific sources Pipeline products
coverage based on various stages of development
ranging from pre-registration till discovery and
undisclosed stages A detailed assessment of
monotherapy and combination therapy pipeline
projects Coverage of the Atrial Fibrillation
pipeline on the basis of target, MoA, route of
administration and molecule type  
5
Report Overview
Reasons to buy  Provides strategically
significant competitor information, analysis, and
insights to formulate effective RD development
strategies Identify emerging players with
potentially strong product portfolio and create
effective counter-strategies to gain competitive
advantage Develop strategic initiatives by
understanding the focus areas of leading
companies Identify and understand important and
diverse types of therapeutics under development
for Atrial Fibrillation Plan mergers and
acquisitions effectively by identifying key
players of the most promising pipeline Devise
corrective measures for pipeline projects by
understanding Atrial Fibrillation pipeline depth
and focus of Indication therapeutics Develop and
design in-licensing and out-licensing strategies
by identifying prospective partners with the most
attractive projects to enhance and expand
business potential and Scope Modify the
therapeutic portfolio by identifying discontinued
projects and understanding the factors that drove
them from pipeline  
6
Table Of Contents
List of Tables 6List of Figures 7Introduction
8Global Markets Direct Report Coverage 8Atrial
Fibrillation Overview 9Therapeutics Development
10Pipeline Products for Atrial Fibrillation -
Overview 10Pipeline Products for Atrial
Fibrillation - Comparative Analysis 11Atrial
Fibrillation - Therapeutics under Development by
Companies 12Atrial Fibrillation - Therapeutics
under Investigation by Universities/Institutes
14Atrial Fibrillation - Pipeline Products Glance
15Late Stage Products 15Clinical Stage Products
16Early Stage Products 17
7
Table Of Contents
Atrial Fibrillation - Products under Development
by Companies 18Atrial Fibrillation - Products
under Investigation by Universities/Institutes
20Atrial Fibrillation - Companies Involved in
Therapeutics Development 21ARCA biopharma, Inc.
21Armetheon, Inc. 22 AstraZeneca Plc
23Bristol-Myers Squibb Company 24Cardiome
Pharma Corp. 25Daiichi Sankyo Company, Limited
26Gilead Sciences, Inc. 27Isis Pharmaceuticals,
Inc. 28Laboratoires Pierre Fabre SA 29Nissan
Chemical Industries, Ltd. 30Nyken BV 31
8
Table Of Contents
Otsuka Holdings Co., Ltd. 32Xention Limited
33Atrial Fibrillation - Therapeutics Assessment
34 Atrial Fibrillation - Therapeutics Assessment
34Assessment by Monotherapy Products
34Assessment by Target 35Assessment by
Mechanism of Action 37Assessment by Route of
Administration 39Assessment by Molecule Type
41 Drug Profiles 43 Enquiry about this report _at_
http//www.researchbeam.com/atrial-fibrillation-pi
peline-review-h2-2015-market/enquire-about-report

9
FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/atrial-fibrillation-pi
peline-review-h2-2015-market
Stay With Us
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE 1 (800) 910-6452 E-MAIL
sales_at_researchbeam.com
About PowerShow.com